Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma

Trial Profile

Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2013

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Doxorubicin; Ifosfamide
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms LIDOXIF
  • Most Recent Events

    • 06 Jul 2013 Planned patient number added to 100 as reported by European Clinical Trials Database record.
    • 06 Jun 2013 Status added to completed as reported by European Clinical Trials Database record.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top